Tag: David Wohl

The UNC Institute for Global Health and Infectious Diseases is now enrolling participants in a fast-track trial of an oral COVID-19 treatment known as Bemnifosbuvir (BEM). Currently, Paxlovid is used for treating COVID-19. However, it is known to interact with common drugs that treat cholesterol, blood clots, and other conditions....

  Eli Lilly today released results of a clinical trial that found bamlanivimab, a monoclonal antibody, significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities. The Phase 3 trial was conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and...

Presented by David Wohl, MD, professor of medicine, UNC Division of Infectious Diseases Wohl is site leader of UNC’s Global Infectious Diseases Clinical Research Group at Chapel Hill. For the past year, during the COVID-19 pandemic, Wohl has been serving as medical director of the COVID-19 vaccination clinics at UNC...

ACTG names second new award for former UNC neurology professor, Kevin Robertson The national AIDS Clinical Trials Group expanded its annual recognition program in 2020 with two new awards named for University of North Carolina faculty members who died in 2019: Charles van der Horst, MD, an infectious diseases physician...

  It’s hot (especially wearing full PPE), it’s tedious, and it’s critical. A volunteer team of UNC infectious diseases faculty members along with UNC hospitalists has been conducting drive-up testing for COVID-19 in Sanford, NC, about 35 miles south of Chapel Hill, twice a month since June, seeing roughly 1,000...

Linghua Li, MD, PhD, is an infectious disease specialist and AIDS clinic director at Eighth People’s Hospital in Guangzhou, China. She did two years of postdoctoral training in infectious diseases at Duke University and at UNC, working with the Institute’s David Wohl, MD. Here, she reports from the frontlines on dealing with COVID-19 in Guangzhou, which...